When was Capsulomics founded?

Capsulomics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Capsulomics located?

Capsulomics is headquartered in Baltimore, United States.

Who is the current CEO of Capsulomics?

Daniel Lunz of Capsulomics. They have also founded 1 company.

How many employees does Capsulomics have?

As of Mar 31, 2026, the latest employee count at Capsulomics is 6.

Is Capsulomics a funded company?

Capsulomics is a funded company, having raised a total of $50K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 22, 2020.

When was the latest funding round of Capsulomics?

Capsulomics' latest funding was a $***** Grant (prize money) round on Nov 22, 2021, with participation from 1 investor. Its primary sector is Gastroenterology. In United States, the Gastroenterology sector has seen $596M in funding in 2026 to date.

Where does Capsulomics rank among its competitors?

Capsulomics ranks 91st amongst 138 active competitors, of which 57 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was 4baseCare, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of Capsulomics?

Capsulomics' top competitors include Geneoscopy, 4baseCare and NeoGenomics. Among them, 4baseCare secured the most recent funding round in July, 2026.

Capsulomics - 2026 Company Profile, Team, Funding & Competitors

Capsulomics is a seed company based in Baltimore (United States), founded in 2018 by Daniel Lunz and Stephen J Meltzer. It operates as a Developer of methylation based diagnostic tests for esophageal cancer risk. Capsulomics has raised $50K in funding. The company has 138 active competitors, including 57 funded and 20 that have exited. Its top competitors include companies like Geneoscopy, 4baseCare and NeoGenomics.

Company Details

Developer of methylation based diagnostic tests for esophageal cancer risk. This diagnostic tool analyzes specific gene methylation markers to determine the probability of progression from non-dysplastic or low-grade Barrett’s esophagus to high-grade dysplasia or esophageal adenocarcinoma. The process involves evaluating DNA methylation status combined with patient age to generate a risk score and category. These results assist clinicians in determining appropriate surveillance intervals or therapeutic interventions for patients.

Website: capsulomics.com
Email ID: *****@capsulomics.com

Key Metrics

Founded Year

2018

Location

Baltimore, United States

Stage

Seed

Total Funding

$50K in 2 rounds

Latest Funding Round

Grant (prize money), Nov 22, 2021, $*****

Investors

TEDCO & 2 more

Ranked

91^st among 138 active competitors

Employee Count

6 as on Mar 31, 2026

Similar Companies

Geneoscopy & 166 more

View Capsulomics' full profile

Capsulomics has raised a total funding of $50K over 2 rounds. Its first funding round was on Jan 22, 2020. Its latest funding round was a Grant (prize money) round on Nov 22, 2021 for $*****. 1 investor participated in its latest round. Capsulomics has 3 institutional investors.

Here is the list of recent funding rounds of Capsulomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 22, 2021	8498737	Grant (prize money)	2727653	2720112	6001925	6494895
Jan 22, 2020	6662671	Seed	2637450	3182362	5460954	4171034

Access funding benchmarks and valuations. Sign up today!

View details of Capsulomics's funding rounds and investors

The founders of Capsulomics are Daniel Lunz and Stephen J Meltzer. Daniel Lunz is the CEO of Capsulomics.

Here are the details of Capsulomics' key team members:

Daniel Lunz: Co-Founder & CEO of Capsulomics.
Stephen J Meltzer: Co-Founder of Capsulomics.

View details of Capsulomics's Founder profiles and Board Members

Capsulomics' employee count trend

Capsulomics has 6 employees as of Mar 26. Here is Capsulomics's employee count trend over the years:

Uncover Capsulomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Capsulomics include Geneoscopy, 4baseCare and NeoGenomics. Here is the list of Top 10 competitors of Capsulomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
2nd	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$25.9M	Tremis Consultancy, Yali Capital & 41 others	67/100
3rd	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	63/100
4th	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	61/100
5th	Cleveland Diagnostics 2013, Cleveland (United States), Series E	Developer of diagnostics technology to detect cancer in early stage	$111M	Novo Holdings, LYFE Capital & 5 others	58/100
6th	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Gates, Oracle & 1 others	58/100
7th	Cyted 2018, Cambridge (United Kingdom), Series B	Leader in non-endoscopic diagnostics for digestive health, enabling early disease detection and access to care for all	$50.4M	Advent Life Sciences, EQT & 3 others	57/100
8th	Lucid Diagnostics 2018, New York City (United States), Public	Developer of diagnostic kit for oesophagal cancer	-	-	53/100
9th	1Cell.Ai 2021, Mumbai (India), Series A	Developer of AI-powered single-cell multi-omic analysis tools for precision oncology	$16M	Celesta Capital, Cedars Sinai & 3 others	52/100
10th	Adela 2021, San Francisco (United States), Series A	Developer of a platform for detection of cancer	$139M	F-Prime Capital, LabCorp & 5 others	51/100
91st	Capsulomics 2018, Baltimore (United States), Seed	Developer of methylation based diagnostic tests for esophageal cancer risk	$50K	TEDCO, Gaingels & 1 others	25/100